Remember also that if Congress re-authorizes the "Priority Review Voucher Program",that CTIX becomes eligible for a Priority Review Voucher which could then be sold for 100's of millions of dollars due to Kevetrin's orphan designation for pediatric retinoblastoma application.

Kelt